Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

South Africa has made history by becoming the first African nation to register Lenacapavir, a revolutionary long-acting ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best ...

Dr Joel Steingo of TB HIV Care says Lenacapavir could be a breakthrough in reducing infections, especially at a time when ...

By William Baloyi When President Donald Trump issued an executive order suspending all foreign aid to South Africa, in ...

SAHPRA chief executive Dr Boitumelo Semete-Makokotlela said the product is “the most effective HIV prevention measure thus ...

The timing of the renewed support is pivotal. South Africa is preparing to roll out Lenacapavir, a groundbreaking long-acting antiretroviral treatment, as early as March or April 2026.

HIV prevention drug Lenacapavir, which has been tested in South Africa during clinical trials, will be made available in the country in 2026 for high-risk groups.

Camber Pharmaceuticals’ parent company, Hetero, a global company specializing in active pharmaceutical ingredients and ...

A newly approved HIV medication provides near-total protection against infection with just two injections a year. It's called Lenacapavir. But the high price of the drug could limit its reach. A newly ...

SAHPRA has registered Lenacapavir, a new six-monthly PrEP injection to prevent HIV-1 in adults and adolescents over 35 kg.